Hosted on MSN19d
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial
The drug was investigated as part of the HEALEY ALS Platform trial. Its primary endpoints were to assess changes in disease severity over time using the ALS Functional Rating Scale-Revised ...
Nasdaq20d
Denali Therapeutics announces HEALEY ALS trial regimen misses endpoints
Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic ...
ALS News Today2d
Zydus cleared to begin US trial of oral therapy usnoflast for ALS
Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
Becker's Hospital Review19d
Google's ALS drug fails phase 3 trial
according to topline results from the Healey ALS platform trial. Fosigotifator did not demonstrate a significant effect on disease progression, combining function and mortality measures ...
Business Insider20d
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Seeking Alpha17d
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].